Medarex and Trillium Collaborate to Develop Human Antibodies

A collaboration for the development of fully human antibody therapeutics has been announced by Medarex, Inc. (Princeton, NJ, USA) and Trillium Therapeutics, Inc. (TTI, Trillium Therapeutics, Toronto, Canada).

Under the agreement, the two companies will share equally the cost and responsibility of the development of antibody products. In addition, the two companies plan to jointly commercialize and share equally any future revenues arising from an antibody product resulting from this collaboration. TTI specializes in developing innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders and graft rejection.
Medarex is a biopharmaceutical company focused on the discovery and development of therapeutics to treat life-threatening and debilitating disease. The company's UltiMAb human antibody development system is a combination of human antibody technologies that enable the rapid creation of fully human antibodies to a wide range of disease targets.

"We believe TTI's expertise in the area of immune-mediated disorders nicely complements Medarex's development capabilities. TTI has provided a promising target to kick-off this collaboration, and I am hopeful that the alliance will be fruitful,” said Donald L. Drakeman, president and CEO of Medarex.





Related Links:
Medarex
Trillium Therapeutics